Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.190
Buy
RSI(14)
59.582
Neutral
STOCH(KDJ)(9,3,3)
66.084
Neutral
ATR(14)
0.324
High Vlolatility
CCI(14)
96.425
Neutral
Williams %R
33.108
Buy
TRIX(12,20)
0.745
Sell
StochRSI(14)
5.438
Sell
Search
Exagen Inc
XGNAdd to Watchlist
3.640USD
-0.210-5.45%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
87.94MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Exagen Inc
Currency: USD Updated: 2026-05-15Key Insights
Exagen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 22 out of 74 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Exagen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Exagen Inc Highlights
StrengthsRisks
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.69% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 66.58M.
Fairly Valued
The company’s latest PE is -4.09, at a medium 3-year percentile range.
Held by First Eagle Investment
Star Investor First Eagle Investment holds 125.24K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.07.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
8.667
Target Price
+125.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Exagen Inc is 7.53, ranking 32 out of 74 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.31M, representing a year-over-year increase of 11.67%, while its net profit experienced a year-over-year increase of 5.73%.
Score
Financials
7.91
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.17
Operational Efficiency
8.98
Growth Potential
7.37
Shareholder Returns
7.20
Exagen Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Exagen Inc is 7.51, ranking 25 out of 74 in the Healthcare Providers & Services industry. Its current P/E ratio is -4.09, which is -80.99% below the recent high of -0.78 and -227.24% above the recent low of -13.39.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 22/74
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Exagen Inc is 8.57, ranking 8 out of 74 in the Healthcare Providers & Services industry. The average price target is 15.00, with a high of 18.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
8.667
Target Price
+125.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
68
Total
7
Median
8
Average
Company name
Ratings
Analysts
Exagen Inc
XGN
7
CVS Health Corp
CVS
29
HCA Healthcare Inc
HCA
27
Teladoc Health Inc
TDOC
27
Tenet Healthcare Corp
THC
24
Universal Health Services Inc
UHS
21
1
2
3
...
14
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Exagen Inc is 9.06, ranking 25 out of 74 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 4.31 and the support level at 2.80, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.730
Sell
MA10
3.382
Buy
MA20
3.108
Buy
MA50
3.053
Buy
MA100
3.780
Sell
MA200
6.665
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exagen Inc is 4.56, ranking 46 out of 74 in the Healthcare Providers & Services industry. The company's beta value is 1.86. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Exagen Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
1.86
VaR
+6.69%
240-Day Maximum Drawdown
+77.84%
240-Day Volatility
+75.83%
Return
Best Daily Return
60 days
+34.92%
120 days
+34.92%
5 years
+42.38%
Worst Daily Return
60 days
-10.31%
120 days
-13.45%
5 years
-24.63%
Sharpe Ratio
60 days
+0.87
120 days
-1.65
5 years
+0.11
Risk Assessment
Maximum Drawdown
240 days
+77.84%
3 years
+77.84%
5 years
+90.58%
Return-to-Drawdown Ratio
240 days
-0.63
3 years
+0.10
5 years
-0.15
Skewness
240 days
+2.63
3 years
+1.52
5 years
+1.65
Volatility
Realised Volatility
240 days
+75.83%
5 years
+102.74%
Standardised True Range
240 days
+10.37%
5 years
+10.67%
Downside Risk-Adjusted Return
120 days
-338.10%
240 days
-338.10%
Maximum Daily Upside Volatility
60 days
+92.60%
Maximum Daily Downside Volatility
60 days
+56.00%
Liquidity
Average Turnover Rate
60 days
+1.69%
120 days
+1.88%
5 years
--
Turnover Deviation
20 days
+109.30%
60 days
+45.21%
120 days
+61.05%
Peer Comparison
Healthcare Providers & Services
Exagen Inc
XGN
7.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Encompass Health Corp
EHC
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Concentra Group Holdings Parent Inc
CON
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Pennant Group Inc
PNTG
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brightspring Health Services Inc
BTSG
8.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Hinge Health Inc
HNGE
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
